Laekna, Inc. (HKG:2105)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
14.00
+0.47 (3.47%)
At close: Mar 10, 2026
-5.02%
Market Cap 5.66B
Revenue (ttm) 5.07M
Net Income (ttm) -263.24M
Shares Out 418.24M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,971,500
Average Volume 2,119,562
Open 13.63
Previous Close 13.53
Day's Range 13.63 - 15.10
52-Week Range 8.10 - 23.50
Beta -1.12
RSI 56.50
Earnings Date Mar 18, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 84
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2105
Full Company Profile

Financial Performance

In 2024, Laekna's revenue was 524,000, an increase of 11.49% compared to the previous year's 470,000. Losses were -254.30 million, -31.05% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.